Skip to content

Biohaven BHVN Preferred Stock, Shares Outstanding

Preferred Stock, Shares Outstanding at other companies

Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
BridgeBio Pharma logo
BridgeBio PharmaBBIO
ADMA Biologics logo
ADMA BiologicsADMA
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesOutstanding.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Biohaven's preferred stock, shares outstanding?
Biohaven (BHVN) reported preferred stock, shares outstanding of $0 in Q1 2026.